Abstract
We identified three novel mutations (p.Gly39Arg, p.Lys157Glu, p.Cys379Gly) and one previously known mutation (p.Asp141Asn) in the von Willebrand factor propeptide from three von Willebrand disease patients. All four mutations impaired multimerization of von Willebrand factor, due to reduced oxidoreductase activity of isomeric propeptide. These mutations resulted in the endothelial reticulum retention and impaired basal and stimulated secretions of von Willebrand factor. Our results support that the mutations in the D1 domain lead to defective multimerization, intracellular trafficking, and secretion of von Willebrand factor and result in bleeding of patients.
Electronic supplementary material
The online version of this article (doi:10.1186/s13045-015-0166-9) contains supplementary material, which is available to authorized users.
Keywords: von Willebrand disease, VWF propeptide, VWF gene mutation, VWF multimerization, ER retention
Findings
Von Willebrand factor propeptide (VWFpp), composed of D1 and D2 domains, is necessary for the multimerization, intracellular trafficking, and secretion of the factor [1–3]. Few mutations in the D1 domain of VWFpp have been reported, and the pathogenic nature of these mutations remains largely unknown [4, 5].
We found three novel mutations (p.Gly39Arg, p.Lys157Glu, p.Cys379Gly) and one previously known mutation (p.Asp141Asn) in the VWFpp from three von Willebrand disease (VWD) patients (Additional file 1). The proband 1 (P1) and proband 2 (P2) were type 3 VWD, while the proband 3 (P3) was type 1 VWD [6]. The laboratory results of these patients and their family members are summarized in Table 1. P1 and P2 presented undetectable von Willebrand factor (VWF) multimer, and P3 exhibited light multimer pattern, compared to normal plasma (NP) (Additional file 2: Figure S1). All mutations are located in the D1 domain of VWFpp.
Table 1.
Family | Members | VWF mutation | Genotype | APTT ratio | PT ratio | TT ratio | VWF: Ag | VWF: RCo | FVIII: C | BS |
---|---|---|---|---|---|---|---|---|---|---|
(sec) | (sec) | (sec) | (IU/dL) | (IU/dL) | (IU/dL) | |||||
F1 | Proband P1 | G39R D141N | Compound heterozygous | 2.24 | 1.07 | 0.97 | 1.0 | 2.3 | 2.0 | 6 |
F1 | Father P1F | D141N | Heterozygous | 1.09 | 1.15 | 1.24 | 48.4 | 50.2 | 73.5 | 0 |
F1 | Mother P1M | G39R | Heterozygous | 1.12 | 1.05 | 0.91 | 30.3 | 36.4 | 50.6 | 1 |
F2 | Proband P2 | K157E C1165R | Compound heterozygous | 1.95 | 1.04 | 0.89 | 3.0 | 2.1 | 3.0 | 6 |
F2 | Father P2F | K157E | Heterozygous | 0.94 | 1.02 | 0.98 | 87.2 | 80.3 | 97.8 | 1 |
F3 | Proband P3 | C379G | Heterozygous | 1.50 | 1.17 | 1.07 | 8.0 | 5.9 | 13.1 | 9 |
F3 | Brother P3B | C379G | Heterozygous | 1.21 | 1.00 | 0.90 | 14.3 | 13.6 | 25.3 | 3 |
Normal range | – | – | – | 0.82–1.18 | 0.86–1.14 | 0.80–1.20 | 50–160 | 50–120 | 50–150 | 0–3 or 0–5a |
PT prothrombin time, APTT activated partial thromboplastin time, TT thrombin time, VWF:Ag, von Willebrand antigen, VWF:RCo von Willebrand factor ristocetin cofactor activity, FVIII:C factor VIII coagulant activity, BS bleeding scores
a0–3 in male, 0–5 in female
To determine whether and how these mutations impair VWF expression and function, we transiently transfected the human embryonic kidney 293 cells (HEK293) with wild type (WT) or VWF mutant constructs and analyzed VWF multimer (Fig. 1a,b). In the supernatant, the WT-VWF showed a full range of multimers similar to NP. Asp141Asn, Lys157Glu, and Cys379Gly mutants each exhibited different degrees of the loss of large- and medium-sized multimers. We also co-transfected Asp141Asn and Gly39Arg mutants and found that a partial VWF protein multimerization was readily detectable. When mutant and WT-VWF were co-transfected into HEK293 cells, the abnormal VWF multimers were all restored (Additional file 3: Figure S2). We examined cell lysates for VWF multimer and found that multimerization from all VWF mutations were inhibited in different levels as showed in the media. To determine the underlying mechanisms of defective VWF multimerization, we employed a previously established dimerization model using D1D2D′D3 fragment of VWF [7, 8]. In this model, the decreased dimerization of D1D2D′D3 indicates the reduced oxidoreductase of mutant VWFpp. Under the non-reducing condition (Fig. 1c), truncated WT (T-WT) VWF formed both D′D3 monomers and dimers in the supernatant. The dimerizations of truncated four variants (T-Gly39Arg, T-Asp141Asn, T-Lys157Glu, and T-Cys379Gly) were reduced, compared to that observed with T-WT. Co-transfection of the T-Gly39Arg and T-Asp141Asn resulted in a modest restoration of dimer formation compared to the single transfection of truncated Gly39Arg. This result indicates that the impaired multimerization is caused by decreased oxidoreductase activity of the isomeric propeptide. Under the reducing condition (Fig. 1d), D′D3 dimers were reduced to D′D3 monomers in both mutant and wild type D1D2D′D3 fragment.
The VWF antigen was measured in the conditioned media and cell lysates of the transiently transfected HEK293 cells (Additional file 4: Figure S3). The expressions of mutant Gly39Arg or Asp141Asn in the supernatant were significantly impaired, at the level of 2.8 ± 0.3 % to 2.5 ± 0.1 % of the WT. However, the expressions of mutant Lys157Glu or Cys379Gly product in the supernatant were less severely decreased at the levels of 26.0 ± 4.1 % and 22.4 ± 3.8 % of the WT. In co-transfection of Gly39Arg and Asp141Asn constructs, only 2.6 ± 0.1 % VWF was detectable in the supernatant, implying that both mutants do not mutually rescue each other from their defects. We also co-transfected the WT and each mutant (Gly39Arg, Asp141Asn, Lys157Glu, or Cys379Gly), and 59.3 ± 4.3 %, 57.3 ± 8.9 %, 86.6 ± 7.1 %, or 33.9 ± 1.2 % of WT were detected, respectively. This suggests that four mutants can be partially restored by the WT. In the cell lysates of single or co-transfected variants, the VWF levels did not changed dramatically.
We found that the level of VWF antigen in the supernatant of HEK-293 cells expressing WT-VWF increased by 2.28-fold after phorbol 12-myristate-13-acetate (PMA) stimulation. However, cells expressing four mutations exhibited no significant changes in VWF antigen secretion upon PMA stimulation (Additional file 5: Figure S4).
By immunofluorescent staining of VWF proteins (Fig. 2a), we found that VWF formed green granules in cells. Only 37.8 ± 9.3 % WT-VWF was observed in the endoplasmic reticulum (ER), while 74.8 ± 2.5 % Gly39Arg, 84.6 ± 3.8 % Asp141Asn, 69.2 ± 3.6 % Lys157Glu, and 74.3 ± 1.8 % Cys379Gly mutants were detected in the ER (Fig. 2b). In the cell lysates, the bands of pro-VWF were predominant, and mature VWF was hardly detectable in the cells expressing Gly39Arg, Asp141Asn, Lys157Glu, and Cys379Gly, compared to that of WT-VWF (Fig. 2c). These results indicate that the mutant VWF are retained in the ER and fail to be transported to the Golgi, resulting in the decreased VWF secretion.
In summary, four mutations in the D1 domain of VWF impair the multimerization of VWF by directly downregulating the oxidoreductase of the propeptide, disrupt the transport of VWF from the ER to the Golgi, and inhibit the basal and regulated secretion of VWF. These defects contribute to the quantitative loss of VWF, leading to the bleeding diathesis of VWD patients.
Acknowledgments
This work was supported by the Jiangsu Provincial Special Program of Medical Science (BL2012005), Jiangsu Province’s Key Medical Center (ZX201102), Natural Science Foundation of Jiangsu Province (BK20140285), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The authors thank Prof. Lijun Xia, Oklahoma Medical Research Foundation and Prof. Xiaosheng Wu, Mayo Clinic, for critical reading and revisions.
Abbreviations
- VWD
von Willebrand disease
- VWF
von Willebrand factor
- ER
endoplasmic reticulum
- VWFpp
VWF propeptide
- P1
proband 1
- P2
proband 2
- P3
proband 3
- NP
normal plasma
- WT
wild type
- PMA
Phorbol 12-myristate-13-acetate
Additional files
Footnotes
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JY and CR were the principal investigators and took primary responsibility for the paper. ZM, JS, JW, JL, and WO performed the laboratory work for this study. XZ, XB, ZW, and ZY recruited the patients. JY and JW wrote the paper. All authors read and approved the final manuscript.
Contributor Information
Jie Yin, Email: yjjessie@163.com.
Zhenni Ma, Email: windfr@163.com.
Jian Su, Email: szjs2001@yahoo.com.
Jiong-Wei Wang, Email: surwang@nus.edu.sg.
Xiaojuan Zhao, Email: jenna20110507@gmail.com.
Jing Ling, Email: koala_a@126.com.
Xia Bai, Email: baixia@suda.edu.cn.
Wanyan Ouyang, Email: 13305275503@163.com.
Zhaoyue Wang, Email: zwang11@sina.com.
Ziqiang Yu, Email: 109334862@qq.com.
Changgeng Ruan, Email: cshcma@medmail.com.cn.
References
- 1.Journet AM, Saffaripour S, Wagner DD. Requirement for both D domains of the propolypeptide in von Willebrand factor multimerization and storage. Thromb Haemost. 1993;70(6):1053–7. [PubMed] [Google Scholar]
- 2.Rosenberg JB, Haberichter SL, Jozwiak MA, Vokac EA, Kroner PA, Fahs SA, et al. The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF. Blood. 2002;100(5):1699–706. doi: 10.1182/blood-2002-03-0789. [DOI] [PubMed] [Google Scholar]
- 3.Michaux G, Hewlett LJ, Messenger SL, Goodeve AC, Peake IR, Daly ME, et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood. 2003;102(7):2452–8. doi: 10.1182/blood-2003-02-0599. [DOI] [PubMed] [Google Scholar]
- 4.Baronciani L, Federici AB, Cozzi G, La Marca S, Punzo M, Rubini V, et al. Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease. Haemophilia. 2008;14(3):549–55. doi: 10.1111/j.1365-2516.2008.01682.x. [DOI] [PubMed] [Google Scholar]
- 5.Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, Berneman Z. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains. Acta Haematol. 2009;121(2–3):111–8. doi: 10.1159/000214851. [DOI] [PubMed] [Google Scholar]
- 6.Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–14. doi: 10.1111/j.1538-7836.2006.02146.x. [DOI] [PubMed] [Google Scholar]
- 7.Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem. 2004;279(48):49982–8. doi: 10.1074/jbc.M408727200. [DOI] [PubMed] [Google Scholar]
- 8.Dang LT, Purvis AR, Huang RH, Westfield LA, Sadler JE. Phylogenetic and functional analysis of histidine residues essential for pH-dependent multimerization of von Willebrand factor. J Biol Chem. 2011;286(29):25763–9. doi: 10.1074/jbc.M111.249151. [DOI] [PMC free article] [PubMed] [Google Scholar]